Integrated Wealth Concepts’s BioMarin Pharmaceuticals BMRN Stock Holding History

Integrated Wealth Concepts’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.83M	Buy	85,447 +71,792	+526%	+$4.19M	0.04%	434
2025 Q4	$812K	Sell	13,655 -835	-6%	-$45.5K	0.01%	867
2025 Q3	$785K	Buy	14,490 +5,078	+54%	+$290K	0.01%	1112
2025 Q2	$517K	Buy	+9,412	New	+$554K	0.01%	1255
2024 Q2	–	Sell	-3,097	Closed	-$270K	–	1652
2024 Q1	$270K	Buy	3,097 +18	+0.6%	+$1.61K	﹤0.01%	1377
2023 Q4	$297K	Sell	3,079 -26	-0.8%	-$2.3K	﹤0.01%	1277
2023 Q3	$275K	Buy	3,105 +622	+25%	+$55.3K	﹤0.01%	1272
2023 Q2	$215K	Buy	+2,483	New	+$234K	﹤0.01%	1388

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integrated Wealth Concepts's BMRN Position: Q1 2026 in Review

Integrated Wealth Concepts increased its BioMarin Pharmaceuticals (BMRN) stake by 526% in Q1 2026, buying an estimated $4.19M and bringing the position to 85,447 shares worth $4.83M. The position accounts for 0.04% of the portfolio, ranked #434.

Integrated Wealth Concepts first reported a position in BMRN in Q2 2023 and has held it in 8 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Integrated Wealth Concepts held 85,447 shares of BioMarin Pharmaceuticals worth $4.83M as of Q1 2026.
Integrated Wealth Concepts bought 71,792 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.19M.
BioMarin Pharmaceuticals made up 0.04% of Integrated Wealth Concepts's portfolio in Q1 2026, its #434 holding.
Integrated Wealth Concepts first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Integrated Wealth Concepts's 13F filing for Q1 2026, filed 15 May 2026.